# A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer

> **NCT00430235** · PHASE2 · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 39 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** BAY 43-9006

## Key facts

- **NCT ID:** NCT00430235
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2010-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430235, "A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00430235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*